Brokerages Set Qiagen (NYSE:QGEN) Target Price at $50.95

Qiagen (NYSE:QGEN) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $50.95.

A number of research firms recently issued reports on QGEN. JPMorgan Chase & Co. raised their price objective on shares of Qiagen from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Thursday, February 8th. Citigroup cut their price objective on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a research report on Thursday, February 8th. Stifel Nicolaus decreased their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a report on Wednesday, May 1st. Finally, Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $49.48 to $51.00 in a report on Friday, February 16th.

Hedge Funds Weigh In On Qiagen

A number of hedge funds have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. lifted its holdings in Qiagen by 1.1% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 684,575 shares of the company’s stock worth $29,361,000 after purchasing an additional 7,549 shares in the last quarter. US Bancorp DE lifted its holdings in shares of Qiagen by 124.4% in the first quarter. US Bancorp DE now owns 75,529 shares of the company’s stock worth $3,247,000 after buying an additional 41,868 shares in the last quarter. Qsemble Capital Management LP bought a new position in shares of Qiagen during the first quarter worth $671,000. Sei Investments Co. increased its holdings in Qiagen by 18.5% in the 1st quarter. Sei Investments Co. now owns 1,417,389 shares of the company’s stock valued at $60,933,000 after acquiring an additional 220,913 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Qiagen in the 1st quarter worth $994,000. Institutional investors own 70.00% of the company’s stock.

Qiagen Price Performance

NYSE QGEN opened at $42.95 on Friday. The stock has a market capitalization of $9.80 billion, a price-to-earnings ratio of 28.80, a PEG ratio of 3.64 and a beta of 0.42. Qiagen has a 1-year low of $34.74 and a 1-year high of $47.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. The business’s fifty day moving average price is $42.49 and its 200-day moving average price is $42.83.

Qiagen (NYSE:QGEN) last posted its earnings results on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $459.00 million for the quarter, compared to the consensus estimate of $453.91 million. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. Qiagen’s revenue was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 earnings per share. On average, equities analysts predict that Qiagen will post 2.09 earnings per share for the current year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.